KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accounts Payables (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Accounts Payables for 16 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 103.91% to $20.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.9 million, a 103.91% increase, with the full-year FY2025 number at $20.9 million, up 103.91% from a year prior.
  • Accounts Payables was $20.9 million for Q4 2025 at Halozyme Therapeutics, up from $15.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $20.9 million in Q4 2025 to a low of $535000.0 in Q1 2021.
  • A 5-year average of $11.3 million and a median of $12.0 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: plummeted 93.57% in 2021, then skyrocketed 1048.15% in 2022.
  • Halozyme Therapeutics' Accounts Payables stood at $1.5 million in 2021, then surged by 1048.15% to $17.7 million in 2022, then tumbled by 33.22% to $11.8 million in 2023, then decreased by 13.26% to $10.2 million in 2024, then surged by 103.91% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Accounts Payables are $20.9 million (Q4 2025), $15.4 million (Q3 2025), and $20.1 million (Q1 2025).